InvestorsHub Logo
Followers 0
Posts 45
Boards Moderated 0
Alias Born 09/01/2009

Re: None

Thursday, 09/04/2014 9:49:33 PM

Thursday, September 04, 2014 9:49:33 PM

Post# of 128495
2nd licensed producer follows tweed in IPO
Please visit the website @ www.organigram.ca to learn about the Company and click on the link for the Investor Presentation:
http://fjet.ca/sites/default/files/Organigram_Investor_Presentation.pdf

OrganiGram is the only fully bilingual licensed producer with high-quality, organic, condition-specific medical marijuana. With no synthetic nutrients, pesticides, herbicides or additives of any kind, the company’s 100% organic products come in five different strains for various objectives, ranging from appetite stimulation for cancer patients to managing chronic pain for arthritis sufferers.

The team’s focus on producing high-quality organic products sets it apart from many other licensed producers and aspiring licensed producers. In many cases, these companies lack significant growing expertise and are more focused on maximizing near-term profits than establishing an infrastructure to create high-quality products that have the potential to capture greater market share.

Management plans to expand its operations to generate more than $30 million in sales and create 40 more jobs by next summer.

Businesses say while pot still has a stigma, that image is changing in Canada and appeals to U.S. and global investors because of its federally regulated program and contrasts with the United States, where medical marijuana is illegal at the national level. The market is expected to generate $3.4 billion a year in taxable sales over the next decade, according to government estimates.

"The investment community is seeing Canada as a safe place to invest due to the regulatory framework," said Chief Executive Denis Arsenault, noting the firm had seen "tremendous" interest from U.S. and Canadian funds.

The company, which received its license in March, began production later in the month and will start shipping the product next week. It has more than 1,000 patients on the waiting list to receive the drug.

OrganiGram has raised $10.6-million so far, and its latest financing this month was oversubscribed by four times, Arsenault said. The company was valued at $36-million based on the recent round.

OrganiGram is listed under the ticker “OGI” in Canada and OGRMF in the US.